ClinicalTrials.gov
public full text
Public Domain
A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Cytisinicline for Vaping Cessation in Adult Smokers#1260399
- Varenicline Versus Cytisine for Smoking Cessation in Primary Care Setting#1100820
- Analysis and Evaluation of Smoking Treatment With Cytisine#1486273
- Varenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders#1377166
- Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes#1060409
Record · ID 1496236
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive